- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02622542
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy (ACUTE-B)
A Randomized Controlled Comparative Study on Effectiveness of Endovascular Repair Versus Best Medical Therapy for Acute Uncomplicated Type B Aortic Dissection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design:
This is a prospective, two-arm, parallel-group, single-center, pragmatic, randomized clinical trial.
Population:
The target population comprises all adult patients aged 18 years and older who present with uncomplicated acute type B aortic dissection. The study sample will include 436 subjects of both genders and any race or ethnicity.
Procedures:
Eligible and consented patients will be enrolled into the study if all eligibility criteria are met and will be randomly allocated to one of the two study arms: BMT vs BMT+TEVAR
Study Duration:
The study is expected to accrue patients over the course of 5 years and total follow up per patient for 5 years. Overall duration of the study is anticipated to be about 10 years for completion of all study endpoints.
Endpoints:
- Primary Outcome: To determine all-cause mortality among both study arms.
- Secondary Outcomes: To assess any major morbidity events (rupture, aortic intervention or reintervention, progression to complicated dissection, aneurysm formation, malperfusion resulting in organ failure, and aorta-specific mortality), as will quality of life measures, temporal discounting assessment and outcomes comparison in an observational cohort of patients who decline to be randomized due to a strong treatment preference.
Risks and Benefits:
Since this study involves only usual care and FDA-approved treatments, the investigators do not expect any additional physical risks to patients beyond those associated with usual care. One discernible risk involved in study participants is an unintentional disclosure of sensitive patient health information.
The participants of this study do not stand to benefit directly from taking part. However, the investigators hope that the results obtained from this study would provide useful information that would help delineate a standard and economical management protocol for acute Type B aortic dissection in future.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Harleen K Sandhu, MD, MPH
- Phone Number: 7134865131
- Email: Harleen.K.Sandhu@uth.tmc.edu
Study Contact Backup
- Name: Kristofer M Charlton-Ouw, MD, FACS
- Phone Number: 713-486-5100
- Email: Kristofer.CharltonOuw@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Department of Cardiothoracic and Vascular Surgery and Memorial Hermann Heart and Vascular Institute - Texas Medical Center
-
Contact:
- Harleen K Sandhu, MD, MPH
- Phone Number: 713-486-5100
- Email: harleen.k.sandhu@uth.tmc.edu
-
Contact:
- Kristofer M Charlton-Ouw, MD
- Phone Number: 713-486-5100
- Email: Kristofer.CharltonOuw@uth.tmc.edu
-
Sub-Investigator:
- Rana O Afifi, MD
-
Principal Investigator:
- Harleen K Sandhu, MD, MPH
-
Sub-Investigator:
- Kristofer M Charlton-Ouw, MD
-
Houston, Texas, United States, 77089
- Recruiting
- Department of Cardiothoracic and Vascular Surgery; Memorial Hermann Hospital Southeast
-
Contact:
- Gordon Martin, MD
- Phone Number: 713-486-1160
-
Contact:
- Naveed Saqib, MD
- Phone Number: 713-486-1160
-
Sub-Investigator:
- Gordon Martin, MD
-
Sub-Investigator:
- Naveed Saqib, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥18 years, regardless of race or ethnicity;
- Diagnosed with uncomplicated ABAD, i.e., a primary entry tear distal to left subclavian artery with no evidence of malperfusion, end-organ ischemia, rupture, or intractable pain, and onset of symptoms is ≤30 days prior to enrollment;
- Patient has been stabilized after the acute event with control of pain and blood pressure using ≤3 intravenous antihypertensive medications;
- Adequate imaging, e.g., CT with contrast (chest + abdomen+ pelvis) is available prior to enrollment; and
- Indicates willingness to comply with the study protocol and is able to provide a written informed consent;
- Meets criteria for inclusion in the National Death Index and Social Security Death Master File.
Exclusion Criteria:
- Diagnosed with Type A aortic dissection;
- Evidence of complicated ABAD;
- Chronic Type B aortic dissection (>6 weeks from onset of symptoms);
- Unable to be randomized and undergo treatment according to protocol within 30 days of symptom onset;
- Diagnosed with traumatic dissection or penetrating ulcer;
- Anatomy is not suitable for TEVAR;
- Previous descending thoracic or abdominal aortic surgery (open or endovascular);
- Unsuitable access sites, including infection at access sites;
- Associated aortic aneurysm (descending aortic diameter ≥5.0 cm);
- Life expectancy <2 years;
- Unable or unlikely to comply with BMT;
- Unable or refuse to comply with follow-up;
- Intend to participate in another trial within 3 months of enrollment;
- Pregnant or breast-feeding;
- Vasculitis or known genetic connective tissue disorder (Marfan's syndrome or Ehlers-Danlos syndrome)
- Active systemic infection;
- Chronic kidney disease stage 3-5 (estimated glomerular filtration rate <60 mL/min/1.73m2);
- Cerebral vascular accident within past 3 months; or
- Clinically significant gastrointestinal bleeding, major surgery, myocardial infarction, or untreated coagulopathy within past 6 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BMT Alone
Patients in this group will be managed with the best medical therapy (BMT) alone
|
Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
|
Experimental: BMT+TEVAR
Patients in this group will be managed with thoracic endovascular aortic repair (TEVAR) in addition to the best medical therapy (BMT)
|
These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 5 years
|
Participants would be followed for a period of 5 years following initial presentation
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Any major morbidity events
Time Frame: 5 years
|
Participants would be followed for a period of 5 years following initial presentation to record any major events (rupture, aortic intervention or reintervention, progression to complicated dissection, aneurysm formation, malperfusion resulting in organ failure, and aorta-specific mortality)
|
5 years
|
Change in Quality of Life assessment
Time Frame: 5 years
|
Participants would be followed for a period of 5 years following initial presentation to assess the change in their quality of life as compared to baseline or prior to disease onset by using Aortic Disease Quality of Life (ADQoL) instrument and the validated general health related quality of life instrument called Short Form -12 (SF-12).
The ADQoL is an instrument that measures the quality of life in 5 major domains - physical limitations, social limitations, general health perceptions, emotional limitations, and aortic-disease specific limitations.
Lower scores on individual subscales and overall are deemed to be poor quality of life and higher scores indicate good quality of life.
the SF-12 is also designed to assess general health related quality of life and is also scored and assessed similarly, i.e, higher scores indicate good general health related quality of life and measures health perception, physical, emotional, and social limitations.
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kristofer M Charlton-Ouw, MD, FACS, University of Texas Health Science Center, UT Medical School Department of Cardiothoracic and Vascular Surgery, Houston
Publications and helpful links
General Publications
- Afifi RO, Sandhu HK, Leake SS, Boutrous ML, Kumar V 3rd, Azizzadeh A, Charlton-Ouw KM, Saqib NU, Nguyen TC, Miller CC 3rd, Safi HJ, Estrera AL. Outcomes of Patients With Acute Type B (DeBakey III) Aortic Dissection: A 13-Year, Single-Center Experience. Circulation. 2015 Aug 25;132(8):748-54. doi: 10.1161/CIRCULATIONAHA.115.015302.
- Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R, Rehders TC, Kundt G, Scheinert D, Czerny M, Kleinfeldt T, Zipfel B, Labrousse L, Ince H; INSTEAD Trial. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation. 2009 Dec 22;120(25):2519-28. doi: 10.1161/CIRCULATIONAHA.109.886408. Epub 2009 Dec 7.
- Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC, Kundt G, Glass A, Scheinert D, Czerny M, Kleinfeldt T, Zipfel B, Labrousse L, Fattori R, Ince H; INSTEAD-XL trial. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv. 2013 Aug;6(4):407-16. doi: 10.1161/CIRCINTERVENTIONS.113.000463. Epub 2013 Aug 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTVS-KC03
- HSC-MS-15-0937 (Other Identifier: University of Texas Health Science Center at Houston IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Distal Aortic Dissection
-
Changhai HospitalThe First Affiliated Hospital with Nanjing Medical University; China Medical... and other collaboratorsUnknownDistal Aortic DissectionChina
-
Centre Cardiologique du NordUniversita degli Studi di Genova; Henri Mondor University Hospital; Pitié-Salpêtrière...Enrolling by invitationAortic Valve Insufficiency | Aortic Diseases | Ascending Aortic Dissection | Aortic Arch | Aortic Root Dissection | Aortic Root Dilatation | Type A Aortic DissectionFrance
-
Assiut UniversityRecruitingAortic Root Aneurysm | Aortic Root DissectionEgypt
-
Petrovsky National Research Centre of SurgeryRecruitingThoracic Aortic Aneurysm | Thoracic Aortic Dissection | Cardiac Valve Disease | Aortic Aneurysm and DissectionRussian Federation
-
University of PennsylvaniaBolton MedicalEnrolling by invitationThoracic Aortic Aneurysm | Thoracic Aortic Dissection | MicroemboliUnited States
-
Braile Biomedica Ind. Com. e Repr. Ltda.RecruitingThoracic Aortic DissectionBrazil
-
The University of Texas Health Science Center,...Washington University School of Medicine; University of Michigan; John Ritter...Active, not recruiting
-
IRCCS San RaffaeleNot yet recruitingAneurysm | Aortic Arch | Dissection, Aortic
-
Hangzhou Endonom Medtech Co., Ltd.RecruitingAortic Aneurysm and DissectionChina
-
Xiaotong HouNot yet recruitingAcute Aortic DissectionChina
Clinical Trials on BMT
-
National Taiwan University HospitalCompletedStroke RehabilitationTaiwan
-
Centre Hospitalier Intercommunal CreteilAssociation pour la recherche des troubles de l'apprentissage; Orthoédition; Association... and other collaboratorsCompletedDevelopmental Disability | Learning Disorders, SpecificFrance, Martinique
-
University of Michigan Rogel Cancer CenterCompletedPatients Undergoing Bone Marrow Transplant (BMT)United States
-
Massachusetts General HospitalRecruitingBone Marrow Transplant ComplicationsUnited States
-
Seattle Children's HospitalNational Institutes of Health (NIH); National Center for Complementary and...CompletedAttention Deficit Hyperactivity DisorderUnited States
-
University of MinnesotaWithdrawnBlood or Marrow TransplantUnited States
-
Vanderbilt UniversityCompletedPhosphoglycerate Kinase (PGK) DeficiencyUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Institutes of Health (NIH); National Institute on Aging (NIA)Active, not recruitingLymphoma | Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Non-Hodgkins Lymphoma | Blood CancerUnited States
-
Ming-Yuan ChihCompleted
-
University Hospital, MontpellierNot yet recruiting